Thrombin activatable fibrinolysis inhibitor (TAFI) and markers of endothelial cell injury in dialyzed patients with diabetic nephropathy

Thrombosis and Haemostasis

Volumn 91, Issue 3, 2004, Pages 480-486

  Małyszko, Jolanta ^a   Małyszko, Jacek S ^a   Hryszko, Tomasz ^a   Myśliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Diabetic nephropathy; Endothelium; Hemodialyses; Peritoneal dialyses; TAFI

Indexed keywords

ALBUMIN; ANTIPLASMIN; ENOXAPARIN; FIBRINOGEN; INSULIN; NADROPARIN; NEO RECORMON; PLASMIN; PROTHROMBIN; RECOMBINANT ERYTHROPOIETIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; TRIACYLGLYCEROL;

ADULT; AGED; ANEMIA; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONCENTRATION (PARAMETERS); CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE MARKER; ENDOTHELIUM INJURY; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; LEUKOCYTE COUNT; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; MULTIVARIATE ANALYSIS; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS; VASCULAR ENDOTHELIUM;

EID: 1642335547     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-04-0243     Document Type: Article

References (47)

1. Kannel, W, McGee D. Diabetes and cardiovascular risk factors: The Framingham Study. Circulation 1979; 59: 8-17
2. Kannel WB, D'Agostino RB, Wilson PWF, et al.. Diabetes, fibrinogen and risk of cardiovascular disease: The Framingham experience. Am Heart J 1990; 120: 672-6.
3. Stamler, J, Vaccaro, O, Neaton, JD, et al.. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TriaI. Diabetes Care 1993; 16: 434-9
4. Takada Y, Urano T, Watanabe I, et al.. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993; 71: 405-15
5. Kwaan, H. Changes in blood coagulation, platelet function, and plasminogen-plasmin system in diabetes. Diabetes 1992; 41: 31-8
6. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetes patients. Diabetes 1993; 42: 1-7
7. Christe M, Fritschi J, Lammle B, et al.. Fifteen coagulation and fibrinolysis parameters in diabetes mellitus and in patients with vasculopathy. Thromb Haemost 1984; 52: 138-43.
8. Małyszko J, Małyszko JS, Mysliwiec M. Platelet function, serotonin and serum lipids in patients with diabetic nephropathy. Pol Arch Med Wewn 1995; 94: 26-31.
9. Małyszko J. Małyszko JS, Mazerska M, et al.. Serum lipids and fibrinolysis in type II diabetes mellitus with nephropathy. Pol Arch Med Wewn 1996; 96: 324-30.
10. Almer RO, Nilsson IM. On fibrinolysis in diabetes mellitus. Acta Med Scand 1975; 198: 101-4.
11. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 5: 125-39.
12. Llach F. Hypercoagulability, renal vein thrombosis and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-33
13. Viener A, Aviram M, Better OS, et al.. Enhanced in vitro platelet aggregation in hemodialysis patients. Nephron 1986; 43: 139-43
14. Toulon P, Jacquot C, Capron L, et al.. Antithrombin III and heparin cofactor II in patients with chronic renal failure undergoing hemodialysis. Thromb Haemost 1987; 57: 263-8
15. Małyszko J, Małyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int 2001; 21: 158-65
16. Nesheim M, Wang W, Boffa M, et al.. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91
17. Bajzar L, Nesheim ME, Morser J, et al.. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 2793-8
18. Wang W, Boffa MB, Bajzar L, et al.. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81
19. Yano Y, Kitagawa N, Gabazza EC, et al.. Increased plasma Thrombin-Activatable Fibrinolysis Inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab 2003; 88: 736-41
20. Blann AD Endothelial cell activation, injury, damage and dysfunction: Separate entities or mutual terms? Blood Coagul Fibrinol 2000; 11: 623-30.
21. Malyszko J, Urano T, Knofler R, et al.. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res 1994; 75: 569-76.
22. Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for determination of fibrinolysis. J Clin Pathol 1959; 12: 215-21.
23. Bajzar L. Thrombin Activatable Fibrinolysis Inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 11: 2511-6
24. Hryszko T, Malyszko J., Małyszko JS, et al.. Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of Thrombin-Activatable Fibrinolysis Activity. Thromb Res 2001; 104: 233-8
25. Hryszko T, Małyszko J., Małyszko JS, et al.. A possible role of thrombin activatable fibrinolysis inhibitor in disturbances of fibrinolytic system in renal transplant recipients. Nephrol Dial Transplant 2001; 16: 1592-6
26. Hori Y, Gabazza EC, Yano Y, et al.. Insulin resistance with increased circulating levels of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 660-5.
27. Yano Y, Gabazza EC, Hori Y, et al.. Association between plasma Thrombin-Activatable Fibrinolysis Inhibitor levels and activated protein C in normotensive type 2 diabetic patients. Diabetes Care 2002; 25: 1245-6.
28. Małyszko J., Suchowierska E, Małyszko JS, et al.. A comprehensive study on hemostasis in CAPD patients treated with erythropoietin. Perit Dial Int 2002; 22, 582-92.
29. Mosnier LO, Buijtenhuijs P, Marx PF, et al.. Identification of thrombin-activatable thrombin inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
30. Rustom R, Leggat H, Tomura HR, et al.. Plasma thrombomodulin in renal disease: Effects of renal function and proteinuria. Clin Nephrol 1998; 50: 337-41.
31. Mosnier LO, von dem Borne PA, Meijers JC, et al.. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
32. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95: 2855-9.
33. Gresele P, Momi S, Berrettini M, et al.. Activated human protein C prevents thrombin-induced thromboembolism in mice. J Clin Invest 1998; 101: 667-76
34. Nakamura Y, Tomura S, Tachibana K, et al.. Enhanced fibrinolytic activity during the course of hemodialysis. Clin Nephrol 1992; 38: 90-6.
35. Tomura S, Nakamura Y, Doi M, et al.. Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis 1996; 27, 848-54.
36. Irish AB, Green FR. Factor VII coagulant activity (VIIc) ahd hypercoagulability in chronic renal disease and dialysis: Relationship with dyslipidemia, inflammation, and factor VII gentotype. Nephrol Dial Transplant 1998; 13: 679-84.
37. Lane DA, Ireland H, Knight I, et al.. The significance of fibrinogen derivates in plasma in human renal failure. Br J Haematol 1984; 56: 251-60.
38. Ishii Y, Yano S, Kanai H, et al.. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron 1996; 73: 407-12.
39. Kobayashi M, Yorioka N, Yamakido M. Hypercoagulability and secondary hyperfibrinolysis may be related to abnormal lipid metabolism in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1997; 76: 56-61
40. Vaziri ND, Gonzales EC, Wang J, et al.. Blood coagulation, fibrinolytic and inhibitory protein in end-stage renal disease: Effect of hemodialysis. Am J Kidney Dis 1994; 23: 828-35.
41. Vaziri ND, Shah GM, Winer RL, et al.. Coagulation cascade, fibrinolytic system, antithrombin III, protein C and protein S in patients maintained on continuous ambulatory peritoneal dialysis. Thromb Res 1989; 53: 173-80.
42. Alwakeel J, Gader Am, Hurieb S, et al.. Coagulation inhibitors and fibrinolytic parameters in patients on peritoneal dialysis and haemodialysis. Int Urol Nephrol 1996; 28: 255-61.
43. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron 1997; 75: 125-39.
44. Opatrny K Jr, Zemanova P, Mares J, et al.. Fibrinolysis defect in long-term hemodialysis patients with type 2 diabetes mellitus and its relation to metabolic disorder. Am J Nephrol 2002; 22: 429-36.
45. Babazono T, Miyamae M, Tomonaga O, et al.. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Adv Perit Dial 1996; 12: 120-5.
46. Kluft C, Meijer P, Biasucci LM, et al.. Plasma levels of TAFI are elevated in patients with unstable angina pectoris (UAP) compared to stable angina pectoris but show no relationship with outcome of UAP. Thromb Haemost 1999; suppl August 1999: 784.
47. Ordonez JD, Hiatt RA, Killebrew EJ, et al.. The increased risk of coronary heart disease associated with nephritic syndrome. Kidney Int 1993; 44: 638-42.